Two suppressor molecules affect 70 genes in leukemiaApril 25, 2008COLUMBUS, Ohio - By restoring two small molecules that are often lost in chronic leukemia, researchers were able to block tumor growth in an animal model. The research, using human chronic lymphocytic leukemia (CLL) cells, also showed that loss of the two molecules affects 70 genes, most of which are involved in critical functions such as cell growth, death, proliferation and metabolism. The findings reveal how the two molecules, called miR-15a and miR-16-1, normally protect against cancer, and suggest a possible new treatment strategy for CLL.
The study, led by researchers at the Ohio State University Comprehensive Cancer Center, was published recently in the Proceedings of the National Academy of Sciences. "These findings give us a signature of 70 deregulated genes that we believe finally explains at the molecular level how these two molecules contribute to CLL," says principal investigator Carlo M. Croce, director of Ohio State's human cancer genetics program. "The identification of these genes could also have important significance for the development of new therapeutic approaches for chronic leukemias." The two molecules are forms of microRNA, tiny molecules that cells use to help regulate the type and amount of proteins they make. In 2005, Croce and his colleagues first showed that these two microRNAs target a gene called Bcl2, which normally helps cells survive by protecting them from accidental self-destruction. In CLL, however, the gene behaves abnormally and helps the leukemic cells survive long after they should have died. Croce and his colleagues believe that loss of the two molecules alters the gene's behavior. For the new study, the investigators first injected mice with leukemia cells in which they had restored the two microRNAs. This completely suppressed tumor growth in three of five animals. Mice injected with leukemic cells that lacked the two molecules, on the other hand, developed significant tumors. "This clearly showed that these two microRNAs can suppress tumor development," says coauthor Muller Fabrri, a researcher in Croce's laboratory. Because each microRNA regulates many genes, the investigators wanted to learn which ones, in addition to Bcl2, are affected in cells lacking the two molecules. First, they measured differences in gene activity in laboratory-grown CLL cells that had either high or low levels of the two molecules. Next, they measured the levels of all the proteins in the two groups of cells. This proteomic analysis revealed 27 proteins with highly altered amounts. These were identified and shown to be involved in cell growth, cell death and cancer development. Last, the researchers used human CLL cells from 16 patients to verify the gene targets. "Together, these extensive experiments revealed the signature of 70 genes controlled by the two microRNAs," Fabbri says. "They show that microRNAs can affect different biochemical pathways in different ways, and they explain at the molecular level what these two miRNAs do in this disease." Ohio State University Medical Center Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Nitrogen Fossil Infant Mortality Robotic Surgery Hepatitis B Pneumococcal Motor Neurons Global Warming Inflammatory Bowel Disease Sleep Apnea Insect ALS Dendritic Cells Pulmonary Embolism Drug Delivery Water Quality HPV vaccine Black Holes Pandemic Longevity Cardiovascular Risk Biodiesel Telomeres Gamma-ray Biopsy
See More: Science News Tags | |||||||||||||||||||||
|
Related Leukemia Current Events and Leukemia News Articles Novel epigenetic markers of melanoma may herald new treatments for patients Melanoma is the most serious form of skin cancer, diagnosed in more than 50,000 new patients in the United States annually. While the rate of incidences continues to rise, survival rate has not improved and the race is on to find the genetic and cellular changes driving melanoma and to devise new means of detection and treatment. Researchers pinpoint a new enemy for tumor-suppressor p53 Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells. Children's Hospital Oakland scientists first to discover new source for harvesting stem cells A groundbreaking study conducted by Children's Hospital & Research Center Oakland is the first to reveal a new avenue for harvesting stem cells from a woman's placenta, or more specifically the discarded placentas of healthy newborns. A new weapon in the war against HIV-AIDS: Combined antiviral and targeted chemotherapy A discovery by a team of Canadian and American researchers could provide new ways to fight HIV-AIDS. According to a new study published in Nature Medicine, HIV-AIDS could be treated through a combination of targeted chemotherapy and current Highly Active Retroviral (HAART) treatments. Research uncovers clues to virus-cancer link In a series of recently-published articles, a research team from the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center has uncovered clues to the development of cancers in AIDS patients. UCLA cancer researchers develop model that may help identify cancer stem cells Researchers at UCLA's Jonsson Comprehensive Cancer Center, on a quest to find lung cancer stem cells, have developed a unique model to allow further investigation into the cells that many believe may be at the root of all lung cancers. Dual role in breast tissue for a protein involved in leukemia A protein known to play a role in growth of some types of leukemia appears to have a mixed function in breast cancer development, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC). A lethal cancer knocked down by one-two drug punch In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are already on the market. Stem cell protein offers a new cancer target A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston. 1 in 10 advanced colon cancer patients worry about prescription drug costs The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial. More Leukemia Current Events and Leukemia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||